Vivacit-E 또는 Longevity PMCF를 사용한 G7 이중 이동성
Vivacit-E® 또는 Longevity® Poly Bearing & Instrumentation을 사용한 G7® Dual Mobility 비구 시스템의 글로벌, 다기관 및 전향적 시판 후 임상 후속 연구
This study is a global, multi-center, prospective, non-controlled, non-randomized, post-market clinical follow-up study. The main objectives of this study are to confirm the long-term safety, performance, and clinical benefits of the G7 Dual Mobility Acetabular System when used with the Vivacit-E or Longevity polyethylene hip bearing and instrumentation in primary total and revision (total) hip arthroplasty
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
상세 설명
The G7 Dual Mobility construct offers dislocation resistance without the need to constrain the femoral head, providing stability and high range of motion. Dual Mobility systems decrease the risk of post-operative instability in high-risk patients in both primary and revision arthroplasties.
This study will enroll up to 358 hips globally, 179 for the Vivacit-E and 179 for the Longevity polyethylene bearings. From the 179 hips per bearing variant, the study will enroll 60 primary and 119 revision arthroplasty hips. The Longevity bearing variant will only be enrolled in the US, as it is not CE marked and unregistered in the APAC market. Vivacit-E bearings will be enrolled globally.
A maximum of 20 study centers will be selected globally. To minimize potential bias and to maximize our ability to assess inter-site differences, each study site will target maximum 24 primary hip arthroplasties and maximum 47 revision hip arthroplasties. Each site is encouraged to enroll both, primary and revision, subjects.
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 해당 없음
연락처 및 위치
연구 장소
-
-
Gyeongsangnam
-
Yangsan, Gyeongsangnam, 대한민국, 50612
- Pusan National University Yangsan Hospital
-
-
Jeollanam-do
-
Hwasun, Jeollanam-do, 대한민국, 58128
- Chonnam National University Hwasun Hospital
-
-
-
-
Arkansas
-
Little Rock, Arkansas, 미국, 72205
- Bowen Hefley Orthopedics
-
-
New Jersey
-
Jersey City, New Jersey, 미국, 07302
- Jersey City Medical Center
-
-
New York
-
New York, New York, 미국, 10021
- Hospital for Special Surgery
-
-
Ohio
-
Cleveland, Ohio, 미국, 44195
- The Cleveland Clinic
-
-
Oregon
-
Eugene, Oregon, 미국, 97401
- Slocum Research & Education Foundation
-
-
Texas
-
Plano, Texas, 미국, 76104
- Medical City Plano Hospital
-
-
-
-
-
Leuven, 벨기에, 3000
- UZ Leuven
-
-
-
-
-
Milan, 이탈리아
- Istituto San Siro
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
-
Patient is 18 to 80 years of age, inclusive
-
Patient is skeletally mature
-
Patient qualifies for (total) hip arthroplasty based on physical exam and medical history including at least one of the following:
- Non-inflammatory degenerative joint disease, including osteoarthritis and avascular necrosis
- Rheumatoid arthritis
- Dislocation risks
- Correction of functional deformity
- Treatment of non-union, femoral neck fracture, and trochanteric fractures of the proximal femur with head involvement, unmanageable by other techniques
- Revision procedures where other treatment or devices have failed.
-
Patient is willing and able to complete scheduled follow-up evaluations as described in the protocol and Informed Consent
-
Patient, or the patient's legally authorized representative (LAR), has participated in the Informed Consent process and is willing and able to sign an IRB/EC approved Informed Consent
Exclusion Criteria:
-
Patient is septic, has an active infection or has osteomyelitis at the affected joint
-
Patient has significant osteoporosis as defined by treating surgeon
-
Patient has metabolic disorder(s) which may impair bone formation
-
Patient has osteomalacia
-
Patient has distant foci of infections which may spread to the implant site
-
Patient has rapid joint destruction, marked bone loss or bone resorption apparent on pre-operative radiographs
-
Patient underwent contralateral THA within 3 months of planned index procedure or has a contralateral THA planned within 3 months of the index procedure
-
Patient is undergoing simultaneous bilateral THA
-
Patient has vascular insufficiency, muscular atrophy at the implant site or neuromuscular disease which are likely to jeopardize the outcome of the surgery.
-
Patient has any concomitant disease which is likely to jeopardize the functioning or success of the implant
-
Patient is known to be pregnant
-
The patient is in a vulnerable population group such as:
- a prisoner
- a known alcohol or drug abuser
- mentally incompetent or unable to understand what participation in this study entails
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위화되지 않음
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
다른: G7 Dual Mobility with Vivacit-E polyethylene bearing in primary THA
Subjects in need of a total hip arthroplasty who meet inclusion/exclusion criteria (anticipated enrollment: 60) |
hip arthroplasty with G7 Dual Mobility Vivacit-E bearing |
|
다른: G7 Dual Mobility with Vivacit-E polyethylene bearing in revision (total) hip arthroplasty
Subjects in need of a revision (total) hip arthroplasty who meet inclusion/exclusion criteria (anticipated enrollment: 119) |
hip arthroplasty with G7 Dual Mobility Vivacit-E bearing |
|
다른: G7 Dual Mobility with Longevity polyethylene bearing in primary THA
Subjects in need of a total hip arthroplasty who meet inclusion/exclusion criteria(anticipated enrollment: 60) |
hip arthroplasty with G7 Dual Mobility Longevity bearing |
|
다른: G7 Dual Mobility with Vivacit-E Longevity bearing in revision (total) hip arthroplasty
Subjects in need of a revision (total) hip arthroplasty who meet inclusion/exclusion criteria (anticipated enrollment: 119) |
hip arthroplasty with G7 Dual Mobility Longevity bearing |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Survival of the implant system
기간: 10 years
|
Survival of the implant system based on removal of the study device |
10 years
|
|
Safety of the implant system
기간: 10 years
|
Safety of the system will be assessed by monitoring the frequency and incidence of adverse events. Relation of the events to implant, instrumentation and/or procedure should be specified. |
10 years
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Modified Harris Hip Score
기간: 10 years
|
The modified Harris Hip Score measures pain, function and functional activities using a self assessment. The overall score runs from 0-100 with 100 representing the best outcome. |
10 years
|
|
Oxford Hip Score
기간: 10 years
|
The Oxford Hip Score measures pain and function using a self assessment. The overall score runs from 0-48 with 48 representing the best outcome. |
10 years
|
|
EQ-5D-5L
기간: 10 years
|
The EQ-5D-5L measures the quality of life using a self assessment. The questionnaire includes 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. |
10 years
|
|
Radiographic Assessment
기간: 5 years
|
X-ray evaluation to find significant radiographic findings such as radiolucency, osteolysis, atrophy, hypertrophy, component migration, device fracture, heterotopic ossification, etc |
5 years
|
공동 작업자 및 조사자
수사관
수사관
- 연구 책임자: Hassan Achakri, Zimmer Biomet
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- CMG2020-42H
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .